Integrative Omics, Chronic Kidney Disease, and Adverse Outcomes in Older Adults
综合组学、慢性肾病和老年人的不良后果
基本信息
- 批准号:10368118
- 负责人:
- 金额:$ 72.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-13 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAdverse eventAffectAgeAlbuminsAlbuminuriaAncillary StudyAreaAtherosclerosis Risk in CommunitiesBenignBiologicalBiological MarkersBloodCardiacCardiovascular DiseasesCaringCase-Control StudiesCessation of lifeChronic Kidney FailureClinicalCommunitiesComplexCpG dinucleotideCreatinineDNADNA MethylationDataDiseaseDisease OutcomeDisease ProgressionDrug TargetingEchocardiographyElderlyEnd stage renal failureEnvironmental ExposureEpigenetic ProcessEtiologyEventFibrosisFiltrationFunctional disorderFundingFunding MechanismsGene ExpressionGenesGeneticGenetic VariationGoalsGrantHeart failureHeterogeneityHospitalizationHourIndividualInflammationInterventionKidneyLettersLongterm Follow-upMeasuresMendelian randomizationMetabolicMethodsMethylationMolecularMultiomic DataNational Institute of Diabetes and Digestive and Kidney DiseasesNetwork-basedOutcomeParticipantPathogenesisPathway AnalysisPathway interactionsPatientsPersonsPhenotypePhysiologyPopulationPreventionProductionPrognosisProteinsProteomicsRenal functionResearch PriorityRiskRisk FactorsSeriesSignal TransductionSiteSystems BiologyTechniquesTissuesUrineVariantVisitadjudicateadverse outcomeage relatedagedatherosclerosis riskbaseclinical riskclinically relevantcohortdisease prognosisdisorder riskdrug developmentepigenetic variationepigenome-wide association studiesepigenomicsexperiencegenetic variantgenome wide association studyheart functionhigh riskhigh throughput technologyimprovedinnovationinsightinterestmetabolomicsmethylation patternmortalitynovelpreventprotein metaboliterisk predictiontherapeutic targettherapy development
项目摘要
PROJECT SUMMARY
Chronic kidney disease (CKD) affects 500 million people worldwide, with the greatest burden among older
adults. People with CKD are at elevated risk for not only end-stage kidney disease, but also cardiovascular
disease, heart failure, and death. Existing treatment for CKD is inadequate, and there is vast, poorly
understood heterogeneity in disease progression. While genome-wide association studies have identified
genetic variants that modulate CKD-associated risk, much of the hereditability of CKD, as well as the molecular
basis for how identified variants regulate disease, remains unexplained.
Our overarching hypothesis is that an integrated approach combining genetics, epigenetics, proteomics,
and metabolomics can yield novel insights into the pathogenesis and prognosis of CKD. Variability in disease
may be due in part to variability in DNA methylation, which changes with age and the metabolic milieu and can
modify gene expression. Advances in high-throughput technology have revolutionized the breadth and
precision of metabolomic and proteomic profiling, enabling unprecedented windows into trans-omic networks.
The objective of this study is to use a systems biology approach to integrate genetic sequence variation with
DNA methylation patterns, proteomics, and metabolomics in order to advance our understanding and
treatment of CKD risk.
The proposed grant will pursue biological pathways that affect CKD risk in the ongoing Atherosclerosis
Risk Communities (ARIC) study, a contemporary, community-based cohort of white and black adults now aged
70 years and older, with plan for replication in two CKD cohorts and further extension to kidney tissue. The
combination of rich phenotyping, comprehensive adjudicated outcomes, and genetic, epigenomic (funded by
this grant), proteomic, and metabolomic data provides a unique opportunity to generate insights into the
molecular basis of CKD, improve CKD risk prediction, and identify a series of candidate pathways and genes
whose products may serve as targets for drug development.
With the long-term goal of improving care in patients with CKD, we aim to discover associations between
kidney function and metabolites, proteins, and related pathways (Aim 1), identifying specific pathways that
provide insight into CKD-associated outcomes, including CKD progression, heart failure, cardiovascular
disease, and mortality (Aim 2), and elucidate genetic and epigenetic variation underlying these candidate
pathways (Aim 3). The study will use a combination of innovative methods and omics data to identify pathways
and genetic variation that are clinical relevant and thus useful in informing the risk prediction and potentially
treatment of patients with CKD.
项目摘要
慢性肾脏疾病(CKD)影响着全球5亿人,其中老年人的负担最大
成年人了CKD患者不仅患终末期肾病的风险增加,而且心血管疾病的风险也增加。
疾病心力衰竭和死亡目前对CKD的治疗是不够的,而且有大量的,
了解疾病进展的异质性。虽然全基因组关联研究已经确定
调节CKD相关风险的遗传变异,CKD的大部分遗传性,以及
然而,对于已确定的变异如何调节疾病的基础,仍然无法解释。
我们的总体假设是,一个综合的方法结合遗传学,表观遗传学,蛋白质组学,
代谢组学可以为CKD的发病机制和预后提供新的见解。疾病变异性
可能部分是由于DNA甲基化的变异性,它随着年龄和代谢环境的变化而变化,
修饰基因表达。高通量技术的进步已经彻底改变了
代谢组学和蛋白质组学分析的精确性,使前所未有的窗口进入transomic网络。
本研究的目的是使用系统生物学方法整合基因序列变异与
DNA甲基化模式,蛋白质组学和代谢组学,以促进我们的理解,
治疗CKD风险。
拟议的拨款将在正在进行的动脉粥样硬化研究中研究影响CKD风险的生物学途径。
风险社区(ARIC)研究,一个当代的,以社区为基础的队列的白色和黑人成年人现在年龄
70岁及以上,计划在两个CKD队列中进行复制,并进一步扩展至肾组织。的
结合丰富的表型,全面的裁定结果,和遗传,表观基因组(由
这项拨款),蛋白质组学和代谢组学数据提供了一个独特的机会,以产生洞察力,
CKD的分子基础,改善CKD风险预测,并确定一系列候选途径和基因
其产品可以作为药物开发的目标。
长期目标是改善慢性肾脏病患者的护理,我们的目标是发现慢性肾脏病患者与慢性肾脏病患者之间的关系。
肾功能和代谢物,蛋白质和相关途径(目标1),确定特定的途径,
深入了解CKD相关结局,包括CKD进展、心力衰竭、心血管
疾病和死亡率(目标2),并阐明这些候选人的遗传和表观遗传变异
路径(目标3)。该研究将使用创新方法和组学数据相结合的方法来确定途径
和遗传变异是临床相关的,因此在告知风险预测和潜在的
治疗CKD患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEF CORESH其他文献
JOSEF CORESH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEF CORESH', 18)}}的其他基金
Long-term effects of hearing intervention on brain health in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized study
老年人衰老和认知健康评估 (ACHIEVE) 随机研究中听力干预对大脑健康的长期影响
- 批准号:
10680434 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
Long-term effects of hearing intervention on brain health in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized study
老年人衰老和认知健康评估 (ACHIEVE) 随机研究中听力干预对大脑健康的长期影响
- 批准号:
10418325 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A
社区动脉粥样硬化风险 (ARIC) 研究 - 现场中心 - 任务令 01,任务区 A
- 批准号:
10788250 - 财政年份:2021
- 资助金额:
$ 72.13万 - 项目类别:
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A
社区动脉粥样硬化风险 (ARIC) 研究 - 现场中心 - 任务令 01,任务区 A
- 批准号:
10620984 - 财政年份:2021
- 资助金额:
$ 72.13万 - 项目类别:
Integrative Omics, Chronic Kidney Disease, and Adverse Outcomes in Older Adults
综合组学、慢性肾病和老年人的不良后果
- 批准号:
10163839 - 财政年份:2020
- 资助金额:
$ 72.13万 - 项目类别:
ARIC - JHU FIELD CENTER - DIVERSITY SUPPLEMENT
ARIC - JHU 野外中心 - 多样性补充
- 批准号:
10054600 - 财政年份:2019
- 资助金额:
$ 72.13万 - 项目类别:
Aging, Cognition, and Hearing Evaluation in Elders (ACHIEVE) Randomized Trial
老年人的衰老、认知和听力评估 (ACHIEVE) 随机试验
- 批准号:
9986336 - 财政年份:2017
- 资助金额:
$ 72.13万 - 项目类别:
Aging, Cognition, and Hearing Evaluation in Elders (ACHIEVE) Randomized Trial
老年人的衰老、认知和听力评估 (ACHIEVE) 随机试验
- 批准号:
9287053 - 财政年份:2017
- 资助金额:
$ 72.13万 - 项目类别:
IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - FIELD CENTER - CORE STUDY OPERATIONS
IGF::OT::IGF 动脉粥样硬化风险社区 - 现场中心 - 核心研究操作
- 批准号:
10329837 - 财政年份:2016
- 资助金额:
$ 72.13万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 72.13万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 72.13万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 72.13万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 72.13万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 72.13万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)